Tacrolimus Envarsus Xr denied for missing prior authorization by Cigna?

Cigna's specific coverage criteria for tacrolimus envarsus xr are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Required Prior Authorization for Tacrolimus Envarsus XR

A prior-authorization-required denial means the claim was processed without the advance approval Cigna requires before dispensing Envarsus XR. This is procedural rather than clinical — Cigna has not said the drug is inappropriate, only that the approval step was not completed before the claim was submitted. Extended-release tacrolimus formulations are commonly subject to prior authorization because they are higher-cost alternatives to immediate-release tacrolimus, and insurers use the PA process to verify clinical justification.

This denial is fully resolvable. The path is to submit the prior authorization — or, if already dispensed, to request a retroactive PA review — with the clinical documentation that meets Cigna's coverage criteria.

## Your Federal Appeal Rights

• Prior authorization appeal: If you submitted a PA and it was denied, you have the right to internal appeal within the timeframe on the denial notice. If you never submitted a PA, the first step is to file one now, or request a retroactive authorization with explanation of the circumstances.
• External review (ACA §2719): If the internal appeal on a PA denial is unsuccessful, you may request independent external review, typically within approximately four months of the final internal decision.
• ERISA §503: Employer-plan members are entitled to full-and-fair review, including written reasons for the PA denial and the criteria applied.
• Expedited PA: If your clinical situation is urgent — for example, a recently transplanted patient needing stable immunosuppression — request an expedited PA review (typically 72-hour turnaround) simultaneously with the standard process.

## What to Gather

1. Cigna's PA criteria: Download the current coverage policy for Envarsus XR from Cigna's online medical/pharmacy policy library before preparing your submission. Build your documentation to answer each criterion specifically. 2. Transplant and diagnosis records: Transplant type, date, and current immunosuppression protocol. 3. Prior tacrolimus history: Chronological record of all tacrolimus formulations used, with dates, trough levels, and clinical outcomes, including any tolerability or variability issues with immediate-release formulations. 4. Clinical stability documentation: Recent lab trends, clinic notes, and any biopsy results. 5. Prescriber PA request letter: Your transplant physician must sign the PA request and provide a narrative explaining how each Cigna criterion is met, referencing the FDA-approved prescribing information for Envarsus XR and the applicable transplant guideline organization.

## Criteria-Mapping Structure

Build the PA submission and any appeal around a direct criterion-by-criterion response:

| Cigna PA Criterion | Chart Documentation That Satisfies It | |---|---| | [Criterion from Cigna policy] | [Specific note, lab, or date from medical record] |

Submitting a well-organized, criterion-matched PA package on the first submission dramatically reduces the likelihood of a medical-necessity denial after the procedural barrier is cleared.